Global burden of liver cancer attributable to drug use: trends from 1990 to 2021 and projections to 2040
Contact us if these videos are not relevant.
Contact us if these videos are not relevant.
View abstract on PubMed
Summary
This summary is machine-generated.Drug use significantly increases liver cancer (LC) deaths globally, with higher rates in women and high Socio-Demographic Index regions. Projections show a decline by 2040, highlighting the need for targeted interventions.
Area Of Science
- Global Health
- Oncology
- Epidemiology
Background
- Liver cancer (LC) represents a substantial global health challenge, with hepatocellular carcinoma (HCC) comprising the majority of cases.
- Drug use, encompassing both legal and illicit substances, is an underrecognized yet significant risk factor for LC, contributing to viral hepatitis, direct liver toxicity, and metabolic issues.
Purpose Of The Study
- To analyze global and regional trends in drug-induced liver cancer (LC) mortality and disease burden from 1990 to 2021.
- To project future trends in drug-induced LC burden up to 2040 using data from the Global Burden of Disease (GBD) 2021 study.
Main Methods
- Analysis of age-standardized death rates (ASDR) and disability-adjusted life years (DALYs) from the GBD 2021 database.
- Utilized estimated annual percentage changes (EAPC) to assess trends and the Bayesian Age-Period-Cohort (BAPC) model for future burden projections.
- Conducted subgroup analyses by sex, age, and Socio-Demographic Index (SDI) to identify specific patterns.
Main Results
- Global deaths from drug-induced LC quadrupled between 1990 and 2021, with ASDR increasing from 0.32 to 0.83 per 100,000 (EAPC=1.81) and DALYs rising from 9.60 to 20.42 per 100,000 (EAPC=1.22).
- Women showed higher relative increases in ASDR (2.36) and DALYs (1.87) compared to men.
- High SDI regions experienced the most significant increases in ASDR and DALYs, while low SDI regions demonstrated slower but consistent growth. Projections indicate a plateau before 2030 and a subsequent decline by 2040.
Conclusions
- The global burden of drug-induced liver cancer has markedly increased, with significant regional and gender-based disparities.
- High SDI regions face the most rapid increase in disease burden, while low SDI regions are experiencing rising mortality and morbidity.
- Urgent, targeted public health interventions are necessary for drug use and LC prevention, especially in high-risk populations and geographical areas.
Contact us if these videos are not relevant.
Contact us if these videos are not relevant.
Related Concept Videos
The biliary system of the liver, crucial for bile secretion and drug excretion, comprises intrahepatic bile ducts that merge to form the common hepatic duct. This duct, carrying hepatic bile, combines with the cystic duct, draining the gallbladder and forming the common bile duct, which empties into the duodenum. Bile, produced by hepatic cells lining the bile canaliculi, is composed primarily of water, bile salts, pigments, electrolytes, and lesser amounts of cholesterol and fatty acids. Bile...
Liver and gallbladder diseases are a significant health concern, with prominent conditions including cirrhosis, hepatitis, non-alcoholic fatty liver disease (NAFLD), and gallstones. Jaundice is a common manifestation of liver and biliary disease.
Cirrhosis is characterized by the scarring of hepatic lobules in the liver, which are replaced by fibrous tissue, affecting the liver's normal functioning. NAFLD, on the other hand, is caused by an excessive build-up of fat in the liver, not...
Multiple disease states can significantly influence the oral drug absorption process by affecting blood flow and the functionality of the gastrointestinal (GI) system. Various GI diseases, including conditions that alter GI motility, such as diarrhea, decreased acid secretions (achlorhydria), and infections, have been associated with reduced drug absorption.
Substances such as alcohol and specific drugs, including antineoplastics, can also negatively impact drug absorption. For instance,...
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
Drug control governance involves the oversight and regulation of pharmaceuticals to ensure their safety and efficacy while preventing illegal drug use and trafficking. Regulatory bodies, including the US Food and Drug Administration (FDA) and the European Union's European Medicines Agency (EMA), play a central role in this process. These agencies evaluate the safety and efficacy of drugs before they can be marketed. They fund clinical trials and assess the benefits and risks associated with...
When it comes to infants and young children, they are typically administered smaller doses of medication in comparison to adults. This is primarily because their organ functions still need to fully develop, meaning their bodies are not as efficient at metabolizing or eliminating drugs. Additionally, their blood-brain barrier is more permeable than in adults. As a result, high concentrations of drugs can easily penetrate the central nervous system (CNS), potentially leading to neurological...